ArticleHepatology international2025
Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study.
Article in Hepatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of PD-1/PD-L1 inhibitors combined with anti-VEGF/TKIs and TACE in uHCC: a meta-analysis.Frontiers in oncology · 2026Pooled it
- Comparison of the efficacy of transarterial chemoembolization combined with different molecular targeted agents and/or immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a systematic review and network meta-analysis.Journal of gastrointestinal oncology · 2026Article
- Identification of the CYP19A1-GPER1 axis as a critical oncogenic driver in hepatocellular carcinoma via AKT activation.Journal of translational medicine · 2026Article
- Peripheral regulatory T cells trajectory predicts progression-free survival in hepatocellular carcinoma patients during on-demand transarterial chemoembolization using joint model: a prospective study.Journal of gastrointestinal oncology · 2026Article
- Nanozyme for precision treatment of hepatocellular carcinoma.Materials today. Bio · 2026Review
- Reply to Letter to Editor "Unresolved heterogeneity in hepatic irAEs: critical limitations in prognostic interpretation for ICI-treated patients".Hepatology international · 2025Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
24 authors.
Funding
Abstract
BACKGROUND AND
aimsTransarterial chemoembolization (TACE) combined with immunotherapy and targeted therapy provides a promising therapy for unresectable hepatocellular carcinoma (HCC). This study aimed to compare the efficacy and safety of TACE combined with atezolizumab and bevacizumab (TACE-Ate-Bev) or atezolizumab and bevacizumab alone (Ate-Bev) as first-line treatment for unresectable HCC.
methodsThis multicenter cohort study recruited patients with unresectable HCC who received TACE-Ate-Bev or Ate-Bev as first-line treatment between July 1, 2020 and December 31, 2023. Inverse probability of treatment weighting (IPTW) was employed to minimize bias. Overall survival (OS), progression-free survival (PFS), and adverse events (AEs) were observed.
results311 patients were included in this analysis, with 152 in the TACE-Ate-Bev group and 159 in the Ate-Bev group. The TACE-Ate-Bev group demonstrated significantly improved OS (26.8 [95% CI 23.1-NR] vs. 14.9 [95% CI 11.4-19.9] months, p < 0.0001) and PFS (16.0 [95% CI 12.8-17.8] vs. 6.5 [95% CI 5.4-7.6] months, p < 0.0001) compared to the Ate-Bev group, both in BCLC stage B (mOS: NR vs. 15.6 months, p < 0.0001; mPFS: 16.9 vs. 6.7 months, p < 0.0001) and BCLC stage C (mOS: 25.2 vs. 14.3 months, p = 0.00018; mPFS: 12.8 vs. 6.5 months, p < 0.0001) disease. After IPTW adjustment, the TACE-Ate-Bev group also demonstrated significantly improved OS and PFS compared to the Ate-Bev group, both in BCLC stage B and BCLC stage C disease. Grade 3-4 AEs were observed in 36 patients (24.3%) in the TACE-Ate-Bev group and 34 (21.4%) in the Ate-Bev group. There was no statistically significant difference in the proportion of gastrointestinal bleeding between the TACE-Ate-Bev and Ate-Bev groups (9.9 vs. 10.1%, p = 0.954).
conclusionTACE-Ate-Bev significantly improves OS and PFS with acceptable toxicity compared with Ate-Bev as first-line therapy for unresectable HCC.
Indexed as
Identifiers
40855224What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.